Seth Cheetham
@sethcheetham.bsky.social
mRNA drug discovery | Deputy-Director BASE mRNA Facility | Associate Professor at the University of Queensland.
Today, a huge milestone for personalised #mRNA therapeutics for inherited disease! A baby with an ultra-rare mitochondrial metabolic disease was treated at UPenn with an mRNA-encoded gene-corrector. The mRNA was made to treat a single individual in just 7 months!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
May 16, 2025 at 4:36 AM
Today, a huge milestone for personalised #mRNA therapeutics for inherited disease! A baby with an ultra-rare mitochondrial metabolic disease was treated at UPenn with an mRNA-encoded gene-corrector. The mRNA was made to treat a single individual in just 7 months!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
The technology is programmable and works with other targeting arms including anti-PSMA (highly expressed on prostate cancer cells) bispecifics. 6/
April 2, 2025 at 4:26 AM
The technology is programmable and works with other targeting arms including anti-PSMA (highly expressed on prostate cancer cells) bispecifics. 6/
Bispecifics can be used by combining with the mRNA-LNP (pre-mixing) or the bispecific can be administered first (pre-targeting). 5/
April 2, 2025 at 4:26 AM
Bispecifics can be used by combining with the mRNA-LNP (pre-mixing) or the bispecific can be administered first (pre-targeting). 5/
As proof of concept we used anti-EGFR bispecifics to deliver mRNA to mouse breast cancer xenografts. The mRNA-payload (luciferase) is very efficiently delivered in vivo. 4/
April 2, 2025 at 4:26 AM
As proof of concept we used anti-EGFR bispecifics to deliver mRNA to mouse breast cancer xenografts. The mRNA-payload (luciferase) is very efficiently delivered in vivo. 4/
To overcome this obstacle we developed bispecific antibodies that bind to PEG on the surface of LNPs and to cell-surface markers. 3/
April 2, 2025 at 4:26 AM
To overcome this obstacle we developed bispecific antibodies that bind to PEG on the surface of LNPs and to cell-surface markers. 3/
Getting a high dose of mRNA to target tissues is one of the toughest problems for broad use of mRNA-LNP therapies. When administered systemically mRNA-LNPs go the liver with little delivery to other tissues. 2/
April 2, 2025 at 4:26 AM
Getting a high dose of mRNA to target tissues is one of the toughest problems for broad use of mRNA-LNP therapies. When administered systemically mRNA-LNPs go the liver with little delivery to other tissues. 2/
Exited to share our latest preprint! mRNA-LNPs are efficiently delivered to healthy livers, but what about liver tumours? Our postdoc @laura-leighton.bsky.social found liver tumours efficiently take up mRNA, enabling next generation mRNA-LNP cancer therapeutics.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
March 20, 2025 at 4:38 AM
Exited to share our latest preprint! mRNA-LNPs are efficiently delivered to healthy livers, but what about liver tumours? Our postdoc @laura-leighton.bsky.social found liver tumours efficiently take up mRNA, enabling next generation mRNA-LNP cancer therapeutics.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Not the best weather forecast for Brisbane 😬
March 2, 2025 at 7:34 AM
Not the best weather forecast for Brisbane 😬
Interested in undertaking a PhD in the transformative field #mRNA cancer vaccines? I have an earmarked #PhD scholarship available for an outstanding domestic student to join our team at UQ and @basemrna.bsky.social. If this sounds like you, get in touch.
study.uq.edu.au/study-option...
study.uq.edu.au/study-option...
January 31, 2025 at 5:41 AM
Interested in undertaking a PhD in the transformative field #mRNA cancer vaccines? I have an earmarked #PhD scholarship available for an outstanding domestic student to join our team at UQ and @basemrna.bsky.social. If this sounds like you, get in touch.
study.uq.edu.au/study-option...
study.uq.edu.au/study-option...
How I imagine our lab animals talk to each other.
December 6, 2024 at 6:13 AM
How I imagine our lab animals talk to each other.
The greatest challenge for #mRNA-LNP therapies is targeting non-liver tissues. To overcome this, we developed customisable bispecific antibodies to tether mRNA-LNPs to cell-surface proteins, achieving efficient and selective mRNA delivery in vivo. Preprint 👇
t.co/0nJj8eVsqC
t.co/0nJj8eVsqC
November 18, 2024 at 6:26 AM
The greatest challenge for #mRNA-LNP therapies is targeting non-liver tissues. To overcome this, we developed customisable bispecific antibodies to tether mRNA-LNPs to cell-surface proteins, achieving efficient and selective mRNA delivery in vivo. Preprint 👇
t.co/0nJj8eVsqC
t.co/0nJj8eVsqC